MNMD
HealthcareMind Medicine (MindMed) Inc. · Biotechnology · $2B
What is Mind Medicine (MindMed) Inc.?
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for brain health disorders spanning psychiatry, addiction, pain, and neurology. Headquartered in Vancouver, Canada, MindMed is working to bring novel psychedelic-derived therapies through clinical development.
MindMed generates no commercial revenue yet — it is a research-stage company advancing a pipeline of investigational drugs. Its lead candidate, MM-120, is being studied in Phase 2 trials for generalized anxiety disorder, ADHD, and chronic pain. MM-110 has completed Phase 1 for opioid withdrawal treatment. A third candidate, MM-402, targets core symptoms of autism spectrum disorder. The company's business model depends entirely on clinical success and eventual regulatory approval or partnership deals.
MindMed was founded in 2016 and is headquartered in Vancouver, Canada.
- MM-120: Phase 2 candidate for generalized anxiety disorder and ADHD
- MM-120: also being evaluated for chronic pain management
- MM-110: completed Phase 1 for opioid withdrawal treatment
- MM-402: investigational therapy for autism spectrum disorder symptoms
Is MNMD a Good Stock to Buy?
UQS Score rates MNMD as Poor overall, reflecting the significant challenges typical of early-stage clinical biopharmaceutical companies.
The one relative bright spot in MindMed's profile is its Risk pillar, which scores Good — suggesting the company's balance sheet or near-term financial runway is less precarious than many peers at a similar development stage. This is a meaningful distinction in a sector where cash burn is a constant concern.
Quality, Moat, and Growth all register as Weak, which is expected for a pre-revenue company with no approved products. Valuation is flagged as Elevated, meaning the current market price may already reflect optimistic assumptions about pipeline success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MNMD pay dividends?
No — Mind Medicine (MindMed) Inc. does not currently pay a dividend.
MindMed does not pay a dividend, which is entirely consistent with its stage of development. As a pre-revenue clinical company, all available capital is directed toward funding trials and advancing its pipeline. Income-focused investors should look elsewhere; any return thesis here is built entirely on long-term pipeline outcomes.
When does MNMD report earnings?
MindMed reports financial results on a quarterly cadence, typical for companies listed on US exchanges.
As a clinical-stage company, MindMed's quarterly reports center on cash position, operating expenses, and pipeline milestones rather than revenue or profit. Investors typically watch for updates on trial enrollment, interim data readouts, and any changes to the company's cash runway.
For the most recent quarter's results and pipeline updates, visit MindMed's investor relations page directly.
MNMD Price History
-55.5% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Mind Medicine (MindMed) Inc.?
Based on Mind Medicine (MindMed) Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MNMD Long-term Outlook
MindMed's fundamental outlook is shaped almost entirely by clinical trial outcomes. With Growth and Quality both rated Weak, the near-term trajectory depends on whether MM-120 or other pipeline candidates generate compelling Phase 2 data. A Valuation rated Elevated means the stock already prices in a degree of optimism that may not yet be supported by clinical evidence. The Good Risk rating offers some reassurance about near-term financial stability, but the path to value creation remains long and uncertain.
Growth drivers
- Positive Phase 2 data readouts for MM-120 in anxiety or ADHD
- Growing clinical and regulatory interest in psychedelic-derived medicines
- Potential partnership or licensing deals with larger pharmaceutical companies
Key risks
- Clinical trial failure or disappointing efficacy data
- Elevated valuation leaving little margin of safety if milestones slip
- Ongoing cash burn with no commercial revenue to offset expenses
MNMD vs Peers
MindMed operates in the broader specialty biopharmaceutical space, where it can be compared to other small-cap clinical and commercial-stage companies.
Innoviva holds royalty interests in commercial respiratory products, giving it a revenue-generating model that contrasts sharply with MindMed's pre-revenue pipeline focus.
Oculis is a clinical-stage ophthalmology company, sharing MindMed's development-stage risk profile but targeting an entirely different therapeutic area.
Ardelyx has advanced beyond the clinical stage with approved products, giving it a commercial revenue base that MindMed has yet to establish.
Frequently Asked Questions
What does MindMed do?
MindMed is a clinical-stage biopharmaceutical company developing treatments for brain health conditions including anxiety, ADHD, opioid withdrawal, chronic pain, and autism spectrum disorder. Its pipeline is built around psychedelic-derived compounds. The company has no approved products or commercial revenue at this stage.
Does MNMD pay dividends?
No, MindMed does not pay a dividend. As a pre-revenue clinical company, it reinvests all available capital into research and development. Investors seeking income should look to dividend-paying equities elsewhere.
When does MNMD report earnings?
MindMed reports on a quarterly cadence. Because it is a clinical-stage company, reports focus on cash runway and pipeline progress rather than revenue. Check MindMed's investor relations page for the most current schedule and recent filings.
Is MNMD a good stock to buy?
UQS Score rates MNMD as Poor overall, driven by Weak scores across Quality, Moat, and Growth pillars. The Risk pillar is a relative positive, but Valuation is flagged as Elevated. Whether it fits your portfolio depends on your risk tolerance and conviction in the pipeline. View the full pillar breakdown on UQS Pro.
Is MNMD overvalued?
UQS Score flags MNMD's Valuation pillar as Elevated, suggesting the current market price may already reflect optimistic assumptions about clinical success. For a company with no approved products or revenue, valuation is inherently speculative and tied to pipeline outcomes.
How does MNMD compare to its competitors?
Compared to peers like Innoviva and Ardelyx, which have commercial-stage revenues, MindMed is at an earlier and riskier point in its development. Oculis shares a similar clinical-stage profile but operates in ophthalmology. MindMed's differentiation lies in its focus on psychedelic-derived neuropsychiatric treatments.
What is MNMD's market cap bracket?
MindMed is classified as a small-cap company. This places it in a segment of the market characterized by higher volatility, limited analyst coverage, and greater sensitivity to clinical or regulatory news compared to larger pharmaceutical companies.
Who founded MindMed?
MindMed was founded in 2016. Founding details are widely available through the company's public filings and investor relations materials for those seeking a full corporate history.
Is MNMD a long-term quality investment?
As a long-term quality indicator, UQS Score currently rates MNMD as Poor. Clinical-stage companies can improve significantly if pipeline milestones are met, but the current pillar profile — Weak across Quality, Moat, and Growth — reflects the substantial uncertainty ahead. Long-term quality depends heavily on trial outcomes.
What is the main competitive advantage of MindMed?
MindMed's potential edge lies in its early positioning in the psychedelic-derived medicine space, a therapeutic area attracting growing scientific and regulatory attention. However, the Moat pillar is currently rated Weak, indicating that durable competitive advantages have not yet been established at this stage of development.
What sector does MNMD belong to?
MindMed operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It sits at the intersection of neuropsychiatry and emerging psychedelic medicine research, a niche that carries both high risk and high potential depending on regulatory and clinical developments.
Is MNMD a growth stock or value stock?
Based on UQS pillar labels, MNMD does not fit neatly into either category. Its Growth pillar is rated Weak — reflecting no revenue growth to measure — while Valuation is Elevated. It is best described as a speculative clinical-stage bet rather than a traditional growth or value play.
Unlock Full MNMD Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS Score and all five pillar scores
- ✓View complete financial metrics and trend data
- ✓Compare MNMD against sector peers side by side
- ✓Access the full analyst-style quality breakdown
- ✓Track pillar changes across quarterly updates
- ✓Explore pre-built screens for clinical-stage healthcare stocks
Pro Analysis
MNMD — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 8, 2026 | 12.5 | 0.0 | 12.0 | 0.0 | 63.3 | 0.0 | +0.3 |
| Apr 14, 2026 | 12.2 | 0.0 | 12.0 | 0.0 | 61.0 | 0.0 | -9.4 |
| Apr 9, 2026 | 21.6 | 0.0 | 50.0 | 0.0 | 61.0 | 0.0 | +9.5 |
| Apr 2, 2026 | 12.1 | 0.0 | 12.0 | 0.0 | 61.0 | 0.0 | — |
MNMD — Pillar Breakdown
Quality
— 0.0/100 (25%)Mind Medicine (MindMed) Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Mind Medicine (MindMed) Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 63.3/100 (15%)Mind Medicine (MindMed) Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Mind Medicine (MindMed) Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 12/100 (25%)Mind Medicine (MindMed) Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MNMD.
Score Composition
Financial Data
More Stock Analysis
How is the MNMD UQS Score Calculated?
The UQS (Unified Quality Score) for Mind Medicine (MindMed) Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Mind Medicine (MindMed) Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Mind Medicine (MindMed) Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.